◀ Back to TNF
CCR2 — TNF
Text-mined interactions from Literome
Weber et al., Atherosclerosis 1999
(Arteriosclerosis) :
Notably, oxLDL counteracted the
TNF-alpha mediated downregulation of
CCR2 and CCR2 dependent transendothelial chemotaxis
Vecchi et al., J Leukoc Biol 1999
:
TNF-alpha down-regulated CC chemokine receptor (CCR)1,
CCR2 , and CCR5 and up-regulated CCR7 mRNA levels, in agreement with functional data
Sica et al., J Immunol 2000
(Ascites...) :
The finding of defective
CCR2 expression in TAM, largely
dependent on local
TNF production, is consistent with previous in vitro data on down-regulation of chemokine receptors by proinflammatory molecules
Saccani et al., Proc Natl Acad Sci U S A 2000
:
We have shown previously that in human monocytes, bacterial lipopolysaccharide, IL-1, and
tumor necrosis factor-alpha induce a rapid down-regulation of the monocyte chemotactic protein-1 receptor
CCR2 ( CC chemokine receptor-2 )
Croitoru-Lamoury et al., Glia 2003
:
Moreover,
TNFalpha and IL-1beta significantly
increase BOB/GPR15,
CCR2 , and V28/CX3CR1 mRNA levels in both models
Feterowski et al., Eur J Immunol 2004
(Acute Disease...) :
Inhibition of
CCR2 directly augmented Toll-like receptor
induced IL-10, but not
TNF and IL-6, production of macrophages in vitro
Ponte et al., Stem Cells 2007
:
TNFalpha increases CCR2,
CCR3 , and CCR4 expression ( as opposed to that of CXCR4 ), together with RANTES membrane binding ...
TNFalpha increases
CCR2 , CCR3, and CCR4 expression ( as opposed to that of CXCR4 ), together with RANTES membrane binding
Elmarakby et al., Hypertension 2007
(Hypertension) :
Renal tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and
CCR2b inhibition
reduced tumor necrosis factor-alpha and intercellular adhesion molecule-1 and increased Cyp2c23 expression
Catley et al., IDrugs 2010
(Asthma...) :
This conference report highlights selected presentations on mAb treatments for asthma, including targeting IL-5, IL-13, IL-9 and
TNFa ,
CCR3 inhibitors , histamine H4 receptor inhibition, novel mouse models of COPD and inhaled antisense asthma therapies